BioNTech Reports Gotistobart Shows Significant Survival Benefit in Phase 3 Lung Cancer Trial
Reuters
8 hours ago
BioNTech Reports Gotistobart Shows Significant Survival Benefit in Phase 3 Lung Cancer Trial
BioNTech SE and OncoC4, Inc. have announced new data from the initial, non-registrational dose-finding phase of the global, randomized Phase 3 PRESERVE-003 clinical trial (NCT05671510) for Gotistobart (BNT316/ONC-392). Gotistobart, a selective Treg-modulator targeting CTLA-4, is being evaluated in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) whose disease progressed following prior anti-PD-$(L)$1 therapy and platinum-based chemotherapy. The candidate demonstrated a clinically relevant overall survival benefit compared to standard chemotherapy and exhibited a manageable safety profile. In the first part of the study, Gotistobart reduced the risk of death by more than half versus standard chemotherapy. Median overall survival for patients receiving Gotistobart was not reached after nearly 15 months of follow-up, whereas the chemotherapy group had a median overall survival of 10 months. These data were presented at the IASLC ASCO 2025 North America Conference on Lung Cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143407-de) on December 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.